New Delhi, June 22, 2016
– The IPM grew at 10% in May 2016
– The IPM was valued at Rs.106, 134 crores and the retail sector was valued at Rs.89,071 crores as of MAT May 2016
– 3.4% IPM affected due to the recent ban imposed by the GOI on 344 drugs; acute therapies form 81% of the total banned portfolio
– In the Banned Portfolio analysis, Respiratory constitutes 43% of the overall value; however all other therapeutic areas see a massive dip since February 2016
– In terms of companies, Top 10 companies affected by the ban contribute to 62% of the overall value of the banned portfolio
– Pfizer though contributing highest to banned portfolio reflects positive growth since last three months
IMS Health Market Reflection Report – May 2016
Corporate Comm India (CCI Newswire)
